Month: December 2017

Brisio Innovations Arranges Private Placement

Mr. Paul Andreola reports

BRISIO INNOVATIONS ANNOUNCES PRIVATE PLACEMENT AND STOCK OPTIONS

Brisio Innovations Inc. intends to complete a non-brokered private placement financing of a minimum of 2.5 million units and up to a maximum of five million units at a price of 20 cents per unit for gross proceeds of a minimum of $500,000 and up to a maximum of $1-million.

Each unit will consist of one common share of the company and one-half of one share purchase warrant. Each whole warrant will entitle the holder thereof to purchase one additional share at a price of 30 cents per share for a period of two years from closing of the financing. In the event that the average closing price is equal to or greater than 45 cents per share for a period of 20 consecutive trading days, the company may accelerate the expiry date of the warrants to a date that is 30 days after the notice of completion of such period.

The proceeds of the financing will be used for general working capital.

The company also announces that it has granted 75,000 stock options to an officer of the company. The options will be exercisable at 23 cents per share and expire on Dec. 29, 2022.

We seek Safe Harbor.

Immunoprecise to Strategically Invest in Serpinx B.V.

IMMUNOPRECISE TO STRATEGICALLY INVEST IN SERPINX B.V.
Victoria, British Columbia, Canada, December 29, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with SERPINx B.V. (“SERPINx“) to strategically invest in the development of recombinant protease inhibitors to treat bradykinin mediated diseases (the “Investment”).
The Investment continues to realize on the Board’s commitment to grow globally through strategic acquisitions and partnerships.

It allows IPA to participate in the building of SERPIN-based protein therapeutics for inflammatory-associated diseases, and furthers IPA’s ambition of becoming a single source provider of services across the full antibody and protein target discovery value chain (antigen design, hit generation, lead selection, lead optimization and lead characterization) and offering the full spectrum of antibody and protein production methodologies (library based technologies, hybridoma methods, transgenic animal based platforms, protein expression platforms and single B cell based technology).

Furthermore, the acquisition enhances the Company’s source of and capacity for developing novel protease inhibitor therapeutics.

“In investing in SERPINx B.V., IPA becomes a leading integrated antibody and protein target solutions company with high value potential therapeutic assets” said Dr. James Kuo, Chairman, Interim President of the Company.
SERPINx
SERPINx BV is a Dutch protein therapeutics company involved in developing novel serine protease inhibitor (SERPIN) therapeutics for inflammatory-associated diseases, in particular angioedema. SERPINS are a superfamily of proteins with similar structures that were identified for their protease inhibition activity .  SERPINx BV has a proprietary collection of novel modified variants of α1-antitrypsins in preclinical development that can be applied for the treatment of bradykinin-mediated diseases that address the major shortcomings of C1Inhibitor (patent applications filed).  
The Investment adds important intellectual property and technology to the Company’s product, service and technology estate.

Terms of Investment with SERPINx
Under the binding letter of intent, IPA will invest  €250,000 for 35% of the capital stock in SERPINx to assist in the development of novel serine protease inhibitor (serpin) for the treatment of bradykinin-mediated diseases in the accordance with the terms of a shareholder agreement satisfactory to the parties (the “Definitive Agreement”) with the right of first option for IPA to acquire the remaining outstanding and issued shares of SERPINx prior to any other third party or prior to any additional funding with any other third party.
The letter of intent also sets forth SERPINx’s commitment to undertake and fund animal trials for its proprietary lead compounds at IPA’s Victoria facilities.
The parties will be entitled to carry out due diligence of each other until January 15, 2018.  Upon the parties completing due diligence to their reasonable satisfaction, the parties will enter into the Shareholder Agreement setting forth the terms and conditions of the Investment by January, 2018.  Completion of any Investment with SERPINx is subject to a number of conditions, including but not limited to, completion of due diligence, negotiation of Shareholder Agreement in respect of such a Investment, the availability of financing on terms acceptable to the Company, and receipt of any required regulatory and shareholder approvals. The Investment cannot be completed until these conditions are satisfied, and there can be no assurance that an Investment will be completed at all.

ImmunoPrecise to Acquire Preclinics GmbH

ImmunoPrecise to Acquire Preclinics GmbH

Canada NewsWire

VICTORIA, Dec. 28, 2017

VICTORIA, Dec. 28, 2017 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with Preclinics GmbH (“Preclinics“) whereby the Company has agreed to acquire all of the issued and outstanding shares of Preclinics (the “Transaction“).

The Transaction continues to realize on the Board’s commitment to grow globally through strategic acquisitions. It contributes significantly to IPA extending its ambition of becoming a single source provider of services across the full antibody discovery value chain (antigen design, hit generation, lead selection, lead optimization and lead characterization) and to offer the full spectrum of antibody production methodologies (library based technologies, hybridoma methods, transgenic animal based platforms and single B cell based technology). Furthermore, the acquisition enhances the Company’s source of and capacity for in vivo and in vitro research and formats.

“In acquiring Preclinics GmbH, IPA continues to build its capacity as a single source provider for the antibody discovery process through pharmacological contract research and research services and capabilities targeted to immunization and production of antisera as well as animal care facilities” said Dr. James Kuo, Chairman, Interim President of the Company.

Preclinics

Preclinics is a privately held company based in Potsdam, Germany which has three separate facilities (Potsdam site; Behring Campus Eystrup and its research farm) which performs in vivo research in rodent models and in vitro research in cell culture and other in vitro formats. Preclinics also offers contract immunization and contract production of antisera, and contract housing and breeding of laboratory animals. Preclinics has developed its own proprietary technology such as ImmunoJunction fusion antibodies for redirecting an existing immunity to a new target and research instruments such as the REVOLYZER for tracking of rodent behaviour and is in the process of developing its own library based technology.

The Transaction adds important intellectual property and technology to the Company’s product, service and technology estate.

Terms of Transaction with Preclinics

Under the binding letter of intent, the Company and Preclinics have agreed to negotiate a definitive agreement (the “Definitive Agreement“) whereby the Company will acquire all of the issued and outstanding shares of Preclinics for €2,300,000 (CAD$3,450,000) (the “Purchase Price“) (A) payable 35% in cash and the remainder by the issuance of common shares of the Company on closing of the Transaction, and (B) an additional €750,000 (CAD $1,125,000) is to be paid in succession payments over a period of 3 years based on continued profitability with  €250,000 (CAD $375,000) within one year, €250,000 (CAD $375,000) in year 2 and €250,000 (CAD $375,000) in year 3 with option of Preclinics’ shareholders to take the payments in cash or equity.

The letter of intent also sets forth the Company’s commitment to fund Preclinics, after being acquired by the Company, and to enter into a separate agreement with Preclinics shareholders on the development and commercialization of Immunojunction.  The CEO and CFO of Preclinics will also enter into a three year management contract, which will include non-solicitation and non-competition clauses.

The parties will be entitled to carry out due diligence of each other until February 28, 2018.  Upon the parties completing due diligence to their reasonable satisfaction, the parties will enter into the Definitive Agreement setting forth the terms and conditions of the Transaction by February 28, 2018. Completion of any transaction with Preclinics is subject to a number of conditions, including but not limited to, completion of due diligence, negotiation of definitive agreements in respect of such a transaction, the availability of financing on terms acceptable to the Company, and receipt of any required regulatory and shareholder approvals. A transaction cannot be completed until these conditions are satisfied, and there can be no assurance that a transaction will be completed at all.

Source here

Immunoprecise Adds Scientific Depth To Its Board of Directors

 IMMUNOPRECISE ADDS SCIENTIFIC DEPTH TO ITS BOARD OF DIRECTORS
Victoria, British Columbia, Canada, December 19, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) is pleased to announce the appointment of Dr. Robert Burke to the Company’s Board of Directors. 
Dr. Robert D. Burke is an Emeritus Professor at the University of Victoria, where he was a faculty member for over 35 years. He has a longstanding research interest in the molecular basis of cellular signaling in early embryonic development.  His research involves production and characterization of antibodies and he employs them extensively with high-resolution optical imaging methods. Dr. Burke has published over 100 peer-reviewed publications and has supervised numerous trainees.  He was Chair of the Department of Biochemistry and Microbiology for 8 years, was on the University of Victoria Senate for 12 years, and served on numerous advisory and management committees nationally and internationally. Dr. Burke completed a BSc (Honours) and a PhD at the University of Alberta.

Dr. Burke fills the vacancy left by the departure of Thomas D’Orazio as director and brings significant scientific depth and experience in the production and characterization of antibodies and will assist the Board in assessing the scientific efficacy of its strategic acquisitions globally.

“With the appointment of Dr. Robert Burke to the Board of Directors, IPA continues its history of bringing leading scientific capability to assist the Company to become a leading integrated antibody solutions company with global reach” said Dr. James Kuo, Chairman, Interim President of the Company.

Renoworks Announces New Interior Moulding Enterprise Customer in Australia and Expands Sales Team to Support Growth

Renoworks Announces New Interior Moulding Enterprise Customer in Australia and Expands Sales Team to Support Growth

Renoworks creates designer solution for new product category
Renoworks well positioned for further growth with experienced sales team in-place   

CALGARY, Dec. 11, 2017 /CNW/ – Renoworks Software Inc. (TSXV: RW)(PINK SHEETS: RWOKF)(“Renoworks” or the “Company”), the leading visualizer for the home remodeling and construction industry, is pleased to announce it recently added an Australian-based interior moulding manufacturer to its platform.

Interior trim and moulding represents an exciting new product category for the Company as it works with additional manufacturers to bring visual solutions to the market and expand its product offerings.  The Australian-based company manufacturers and supplies specialized mouldings and architectural building products to all areas of the construction industry.  This manufacturer becomes the third enterprise customer on Renoworks’ platform to be based out of Australia.

“Renoworks continues to provide cost-effective solutions and expand its offerings into new categories,” said Doug Vickerson, CEO of Renoworks.  “With over a million unique users a year on our platform, our partners and customers are seeing the benefit of working with us.”

Mr. Vickerson continued, “Interestingly, the addition of another manufacturer outside our current North America focus illustrates the global potential as we continue to expand our industry reach.  In North America alone, there is a sizeable market segment with approximately 5,000 building products manufacturers and we’ve only begun to scratch the surface.”

The Company is also pleased to report that it has completed the expansion of its sales team to support its strategic growth.  The new hires bring substantial experience and will complement the existing sales team and drive the sales initiatives for the Company’s multiple business units across all its applications.

Mr. Vickerson said of the hiring, “In response to the increasing demand in all of our business units we have once again expanded our sales team.  We now have all the components in-place both from a sales and operational standpoint to capitalize on our current momentum and position our Company for significant sales growth for 2018 and beyond.”

For over 18 years, Renoworks has offered building product manufacturers various digital marketing and sales solutions that showcase their products in a realistic, true-to-life manner.    By utilizing the Renoworks digital visualization platform, manufacturers of exterior and interior building products benefit from increased interactive engagement through web sites and mobile devices., resulting in an increased number of homeowner leads, better understanding of specific homeowner interests, and a rich compilation of user data they receive using the Renoworks platform.  For more information on Renoworks solutions, visit the Company’s website at http://renoworks.com/our-work/.

 

Newswire: Renoworks Announces New Interior Moulding Enterprise Customer in Australia and Expands Sales Team to Support Growth

ImmunoPrecise Antibodies’ chairman sets out ambitious growth plans after it wraps up its latest deal

IPA wants to emulate the success of Invitrogen, which became Life Technologies before being taken over by Thermo Fisher for US$13.6bn..

The business provides custom antibody development and production services and protein expression for drugs R&D

In a major statement of intent, ImmunoPrecise Antibodies Ltd (CVE:IPA) last week said it was buying ModiQuest Research – a deal that’s expected to immediately enhance earnings.

At almost C$11mln, it is the largest of three recent transactions and is part of a roll-up strategy designed to create a significant new force in research tools used by drugs developers.

Emulate the success of Invitrogen ..

IPA wants to emulate the success of Invitrogen, which became Life Technologies before being taken over by Thermo Fisher for US$13.6bn.

Invitrogen’s bedrock business was selling kits for molecular cloning, but a series of well-judged acquisitions transformed it into the go-to supplier to the biotechnology industry.

IPA, which has been around for 25 years but only listed on the Toronto Venture Exchange a year ago, is at the start of a similar journey.

Before we delve further into strategy, it’s worth understanding what the company does and the backdrop against which it is working.

The business as it stands today provides custom antibody development and production services and protein Expression for drugs R&D.

Its customers tend to be pharma and biotech companies as well as non-profit research; so universities, medical charities and grant-funded collaborations.

IPA might get involved initially with a “test, or demonstration, or feasibility analysis”, says chairman James Kuo. That may then lead to a contract or contracts that could run for several years.

In high demand …

Its services are in high demand, given the changes in the multi-billion dollar drugs business over the last decade.

There has been a shift from the screening of traditional small-molecule chemical pharmaceuticals to bespoke biologicals, many of which are monoclonal antibodies (MABs) designed to safely and effectively tackle cancer, rheumatoid arthritis and even psoriasis.

In the US, insurers have shown a willingness to pay for the treatments, which tend to be quite expensive, while patients are demanding best-in-class biologicals that are highly targeted for grievous diseases and generally less toxic.

“The industry has been completely transformed in the last ten years,” says IPA chairman Kuo.

“The focus on small molecule pharmaceuticals for chronic diseases of aging such as hypertension and hyperlipidemias has shifted towards medications that have immuno-biology at their core.

“Now you look at the top selling drugs and they are biologicals – humanized monoclonal antibodies are the mainstay.”

A thriving sector …

Servicing this large and thriving sector could potentially be a very lucrative line of business.

At the moment the monoclonal antibody research tools space is fragmented with scores of small companies providing a myriad of different services.

Big pharma, by contrast, is crying out for a one-stop shop that caters for the majority of its needs.

Management at Invitrogen recognised this when it set out on its epic growth journey in the early 1990s, and IPA’s team think the same demand exists within the monoclonal antibody space.

The opportunities are there to provide the scale, says Kuo.

“There are mom and pop businesses and small companies that have hit a ceiling for growth that might be amenable to be bought for a fair price,” he reveals.

“There are acquisitions in Europe and the US and a few other places too.”

ModiQuest, a specialist in generating MABs, adds significantly to the size of IPA and broadens its footprint in Europe, building on the deals to acquire Netherlands-based U-Protein Express, and QVQ.

There are economies of scale that come with rolling up businesses in this way as well as cross-selling opportunities and other synergies. Value is also created by adding significant new intellectual property to the portfolio.

Working on several deals..

Kuo says the company is working on several deals at any one time and there’s a healthy pipeline of future opportunities.

Investors are supportive of the buy-and-build strategy and the IPA chairman is certain they will be willing to fund the right acquisitions when they come along.

Kuo likens the company’s approach to that of private equity (PE), which enters an industry sector via a series of deals to own that particular area of business.

There are some obvious differences between PE and a company like IPA. For PE it is about financial engineering and the ability to service debt while paying private equity management fees.

These funds then tend to be run by accountants and analysts – which may work if you are selling pots and pans but doesn’t work so well in a specialist area such as research tools.

industry expertise …

IPA has industry expertise in abundance, starting with Kuo, who has led a number of biotechs, worked in big pharma and headed a venture capital fund.

Chief executive Robert Beecroft, businessman and entrepreneur Guy Champagne and fellow directors Greg Smith and Thomas D’Orazio have similarly impressive resumes.

“We have the people who can look at how good and competitive a technology is and make a decision as to whether we might be overpaying,” Kuo explains.

Those who have tracked the company since its IPO last December, will know it has been through a management a shake-up that saw chairman Kuo become interim president.

The press release refers to it as a “re-alignment” and Kuo sketches in a little more detail: “This was not about personalities; the board has very high expectations for the growth trajectory of the company and it didn’t feel they were being met.”

So just what are those expectations and how quickly can IPA become a company of scale?

“I don’t think a business is worth doing unless it has US$1bn potential in a reasonably short period of time, say two years,” explains Kuo.

“I think we are going to succeed and everyone on the team has a similar feeling.”

Proactive Investors UK: ImmunoPrecise Antibodies’ chairman sets out ambitious growth plans after it wraps up its latest deal

ImmunoPrecise to Acquire ModiQuest Research BV

VICTORIA, Dec. 7, 2017 /PRNewswire/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with ModiQuest Research BV (“ModiQuest“) whereby the Company has agreed to acquire all of the issued and outstanding shares of ModiQuest (the “Transaction“).

The Transaction continues to realize on the Board’s commitment to grow globally through strategic acquisitions. It allows IPA to become a single source provider of services across the full antibody discovery value chain (antigen design, hit generation, lead selection, lead optimization and lead characterization) and to offer the full spectrum of antibody production methodologies (library based technologies, hybridoma methods, transgenic animal based platforms and single B cell based technology). Furthermore, the acquisition enhances the Company’s capacity for generating human antibodies.

“In acquiring ModiQuest Research B.V., IPA becomes a leading integrated antibody solutions company with global reach,” said Dr. James Kuo, Chairman, Interim President of the Company.

ModiQuest

ModiQuest is a privately held company based in Oss, The Netherlands that specializes in the generation of monoclonal antibodies against difficult target antigens. ModiQuest applies proprietary technologies to all aspects of the antibody discovery process in research and development, diagnostic and therapeutic applications. Using its proprietary ModiFuse™ (hybridoma electrofusion), ModiSelect™ (B-cell selection) and ModiPhage™ (phage display) technologies, ModiQuest can generate very large panels of monoclonal antibodies from various backgrounds including mouse, rat, rabbit, chicken, llama and human, as well as transgenic animals harboring the human antibody gene repertoire. ModiQuest serves clients in Europe, the US, Asia and Russia. During its year-ended 2016, ModiQuest had revenues of €2,009,374 (CAD $3,037,249) and earnings of €671,799 (CAD $1,015,451).

The Transaction is accretive in both revenue and earnings and brings additional scientific and management capacity.

 

https://web.tmxmoney.com/article.php?newsid=8801704630996905&qm_symbol=IPA

 

Brisio Innovations Announces Resignation and Appointment of Directors

VANCOUVER, BRITISH COLUMBIA / TheNewswire / December 4, 2017 — Brisio Innovations Inc. (CSE: BZI) (PINKSHEETS: NTCEF) (the “Company”) announces that Steven Vestergaard has resigned from the Board of Directors, and Mr. Kristaps Ronka was appointed to the Board of Directors effective December 1.

Kristaps Ronka is an entrepreneur, investor and advisor. Kristaps co-founded AdParlor in 2007, a Toronto-based bootstrapped company that in 4 years become the leader in handling large Facebook Ad campaigns reaching a $100 million run rate. In 2011, Kristaps was named in Inc.’s “Top 30 under 30” most promising young entrepreneurs for disrupting the industry with a visionary approach. AdParlor was acquired in 2011.

Kristaps has since focused on advising and backing start-up companies that are solving important problems and building disruptive technologies from transportation to medicine. His extensive knowledge of business management, new technologies and his network of established contacts will be a valued contribution to the Brisio management team.

Paul Andreola, Brisio CEO states “We welcome Kristaps to the Brisio team. With significant recent developments in applied science such as artificial intelligence and blockchain his extensive knowledge of new and innovative technologies will be put to good use as we continue to evaluate a variety of new investment opportunities.”

Brisio wishes to thank Mr. Vestergaard for his contribution to the Company and wishes him the very best in his future endeavours.

Brisio Innovations Inc.
Paul Andreola

President, CEO and Director
(604) 644-0072
www.brisio.com

https://www.thenewswire.com/archives/kWVFZ5en-brisio-innovations-announces-resignation-and-appointment-of-directors.html

Scroll to top